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Background: The role of tumor matrix metalloproteinase-9 (MMP-9) expression in non-small cell lung cancer
(NSCLC) remains controversial. In this study, we investigated the prognostic value of tumor MMP-9 expression and
other clinicopathologic factors in patients with completely resected NSCLC.
Methods: This retrospective study included patients who underwent complete resection of pathological stage
I–IIIA NSCLC at Severance Hospital, Seoul, Korea, between 1998 and 2009. Tumor samples of 417 patients were
stained by immunohistochemistry, and the expression of MMP-9 in tumor cells was evaluated, using the median
immunohistochemical score of 10 (range, 0-300) as the cut-off.
Results: Tumor MMP-9 expression was observed in 161 (38.6%) of 417 patients. Log-rank analysis showed a
significant association of tumor MMP-9 expression with shortened disease-free survival (p = 0.01) but not with
overall survival (p = 0.109). Multivariate analysis demonstrated that tumor MMP-9 expression was not an independent
prognostic factor of recurrence (p = 0.142) or survival (p = 0.807). However, among patients with adenocarcinoma,
tumor MMP-9 expression was associated with relapse (p = 0.003) and poor survival (p = 0.033). Furthermore, tumor
MMP-9 expression was an independent prognostic indicator of relapse in patients with adenocarcinoma (p = 0.035).
Conclusions: Among patients with NSCLC, tumor MMP-9 expression was associated with poor outcomes in those with
adenocarcinoma, but not in those with squamous cell carcinoma. In addition, MMP-9 expression was identified as an
independent predictor of relapse of completely resected lung adenocarcinoma.
Keywords: Matrix metalloproteinase-9 (MMP-9), Immunohistochemistry, Non-small cell lung cancer (NSCLC), Lung
adenocarcinoma, Prognostic factorBackground
Lung cancer is the leading cause of cancer death in the
United States, and the 5-year survival for non-small cell
lung cancer (NSCLC) of all stages is only approximately
15% [1,2]. Surgical resection is typically performed for
early-stage NSCLC, however even among patients whose
tumors are successfully resected, the 5-year survival rate
is only 50–60%, and for certain patients, recurrence oc-
curs within a few years following resection. In addition,
NSCLC patients with the same stage may show different
patterns of disease progression [3-5]. Therefore, it is im-
portant to identify molecular prognostic markers for* Correspondence: kychu@yuhs.ac
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unless otherwise stated.NSCLC that may guide the use of adjuvant therapy after
surgical resection.
Numerous studies have demonstrated that the expres-
sion of matrix metalloproteinases (MMPs) is associated
with lung cancer prognosis [6-8]. MMPs are associated
with degradation of the extracellular matrix and are
thought to play important roles in tumor invasion and
metastasis [9]. Among the many MMPs, MMP-9 (gelati-
nase-B), a 92-kDa gelatinase that can catalyze type IV
collagen in the basal membrane, is considered a key en-
zyme. MMP-9 has been reported to facilitate tumor
growth, invasion, and angiogenesis [10,11].
Recently, many studies have used immunohistochemical
(IHC) analysis to investigate MMP-9 expression in
resected tumors. These have demonstrated a correlation
between MMP-9 expression and prognosis [12-15]. How-
ever, the clinical efficacy of tumor MMP-9 expression as ais is an Open Access article distributed under the terms of the Creative
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mains controversial [16,17]. Moreover, there is disagree-
ment on how best to define positive IHC staining for
MMP-9.
This study was designed to investigate the expression
of tumor MMP-9 in operable NSCLC and to analyze the
relationship between tumor MMP-9 expression and
prognosis. Furthermore, this study assessed the impact
of tumor MMP-9 expression on the prognosis and out-
come of patients with operable NSCLC.
Methods
Patients
This was a retrospective study of 473 patients with stage
I–IIIA NSCLC who underwent radical resection of pri-
mary lung cancer at Severance Hospital between 1998
and 2009. This study was approved by the Institutional
Review Board of the Yonsei University College of
Medicine. The IRB waived the requirement of individual
patient consent because the analysis was retrospective in
nature. Patients were excluded according to the following
criteria: (1) radiotherapy or chemotherapy prior to surgery,
(2) tumor tissue not available, (3) pathological stage IIIB
or stage IV disease, (4) complete resection not achieved
(not R0), and (5) postoperative survival <60 days.
In total, 417 patients met the selection criteria and
were included in the analysis. Preoperative evaluations
included routine chest radiography, bronchoscopy,Figure 1 Immunohistochemical analyses of NSCLC representing differ
expression; (B) tumor MMP-9 expression; (C) negative control.computed tomography of the chest, abdominal sonog-
raphy, and a bone scan or 18 F-fluorodeoxyglucose
positron emission tomography (18FDG-PET). Post-
operatively, follow-up was achieved through regular
clinic visits until the patient’s death. Patients were
examined by chest computed tomography at 3-month
intervals for 2 years and at 6-month intervals thereafter.
Furthermore, abdominal sonography or 18FDG-PET or
bone scans was performed at 6-month intervals for 5 years
and at 1-year intervals thereafter, and since 2007 18FDG-
PET has been used instead of abdominal sonography.
Paraffin-embedded tumor specimens were used to cre-
ate tissue microarray blocks with 2-mm diameter cores
for IHC staining. Two tissue cores were obtained from
each patient. Pathologic staging was classified according
to the 7th edition of the Union for International Cancer
Control tumor-node-metastasis classification of lung
cancer.Immunohistochemical staining
Formalin-fixed and paraffin-embedded tissues were sec-
tioned at a thickness of 4 μm and stained using an auto-
mated immunostainer (Discovery XT; Ventana Medical
Systems, Tucson, AZ, USA). The slides were dried at 60°C
for 1 hour and deparaffinized using EZ Prep (Ventana
Medical Systems) at 75°C for 8 minutes. Cell conditioning
was performed using CC1 solution (Ventana Medicalent expression levels for tumor MMP-9. (A) No tumor MMP-9
Table 1 Patient characteristics
Tumor MMP-9 P
No Expression
N (%)
Expression
N (%)
Age 0.820
Below median 137 (53.5) 88 (54.7)
Above median 119 (46.5) 73 (45.3)
Sex 0.099
Male 179 (69.9) 100 (62.1)
Female 77 (30.1) 61 (37.9)
Histology 0.001
Squamous cell 130 (50.8) 45 (28.0)
Adenocarcinoma 103 (40.2) 99 (61.5)
Large cell 11 (4.3) 9 (5.5)
Others 12 (4.7) 8 (5.0)
Stage 0.001
I 158 (61.7) 77 (47.8)
II 70 (27.4) 51 (31.7)
IIIA 28 (10.9) 33 (20.5)
T stage 0.068
T1 75 (29.3) 33 (20.5)
T2 147 (57.4) 105 (65.2)
T3 32 (12.5) 18 (11.2)
T4 2 (0.8) 5 (3.1)
N stage 0.002
N0 204 (79.7) 108 (67.1)
N1 35 (13.7) 30 (18.6)
N2 17 (6.6) 23 (14.3)
Lymphovascular invasion 0.549
No 224 (87.5) 144 (89.4)
Yes 32 (12.5) 17 (10.6)
Postoperative Treatment 0.000
Chemotherapy 73 (28.5) 71 (44.1)
Radiation therapy 7 (2.7) 2 (1.2)
Combination therapy 19 (7.4) 20 (12.4)
No treatment 157 (61.3) 68 (42.2)
MMP-9: matrix metalloproteinase-9; Combination therapy:
Chemotherapy + Radiation therapy.
Lee et al. Journal of Cardiothoracic Surgery  (2015) 10:44 Page 3 of 8Systems) at 100°C for 48 minutes. MMP-9 antibody
(rabbit polyclonal antibody, 1:50 dilution; Diagnostic
Biosystems, Pleasanton, CA, USA) was applied to the
slides and incubated at 37°C for 32 minutes. Signals
were detected using a DAB Map Detection Kit (Ventana
Medical Systems). Counterstaining was performed with
hematoxylin (Ventana Medical Systems) for 4 minutes at
room temperature. We performed immunohistochemistry
without the primary antibody as negative control.
Evaluation of tumor MMP-9 expression
IHC staining of tumor sections was reviewed and scored
independently by 2 observers who were blinded to the
clinical data. The staining intensity was classified as
absent (score of 0), weak (score of 1), moderate (score of
2),or strong (score of 3). The extent of staining, defined
as the percentage of positively stained cancer cells, was
evaluated using a continuous scale (range, 0-100 %). The
final IHC score for tumor MMP-9 expression was
obtained by multiplying the staining intensity and the
extent of staining. For statistical analysis, expression
levels were classified according to the median IHC
score (IHC score = 10) as no tumor MMP-9 expression
(IHC score < 10) or tumor MMP-9 expression (IHC
score ≥ 10) (Figure 1).
Statistical analysis
Differences in MMP-9 expression and clinicopathologic
variables were analyzed using the χ2 test. Age was di-
chotomized at the median value. Disease-free survival
(DFS) was defined as the time from surgery to lung can-
cer recurrence, and overall survival (OS) was defined as
the time between surgery and death from any cause. Re-
lapse was defined as diagnosis of distant metastasis or
local recurrence. Postoperative survival was analyzed
using the Kaplan-Meier method and compared using the
log-rank test. Multivariate analysis was performed using
the Cox proportional hazards regression model with a
forward selection procedure to study the effects of dif-
ferent variables on recurrence and survival. A p value
less than 0.05 was considered statistically significant. All
statistical manipulations were performed using the SPSS
software program (SPSS Inc., Chicago, IL, USA).
Results
Patient population
A total of 417 patients were included in the study. The
study included 279 men and 138 women, with a median
age of 61 years (range, 30-81 years). The median follow-
up period was 56.9 months (range, 3-168 months), and
no patients were lost to follow-up. Relapse was observed
in 114 patients, and in total, 150 patients died during
the observation period. The patients’ characteristics are
shown in Table 1.Evaluation of MMP-9 expression
Of the 417 patients, 256 (61.4%) did not show tumor
MMP-9 expression and 161 (38.6%) did show tumor
MMP-9 expression. There was no significant difference
in age, sex, and lymphovascular invasion (LVI) between
these 2 groups. The group with tumor MMP-9 expres-
sion had a higher proportion of patients with adenocar-
cinoma histology (40.2% vs. 61.5%; p = 0.001) and more
advanced stage (p = 0.001). Adjuvant therapy was admin-
istered more often in tumor MMP-9 expression group
Figure 2 Kaplan-Meier survival curves of the relationship between tumor MMP-9 expression and disease-free survival according to
tumor histology. (A) Overall tumor histology; (B) Squamous cell carcinoma; (C) Adenocarcinoma.
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in the frequency of adjuvant therapy for patients with
stage II or IIIA (72.4% vs. 71.4%; p = 0.879). Occurrence
of relapse (21.9% vs. 36.0%; p = 0.002) and death (34.8%
vs. 37.9%; p = 0.518) was higher among patients with
tumor MMP-9 expression.
Analysis of DFS and OS
Univariate analysis revealed a relationship between tumor
MMP-9 expression and DFS in patients with operable
NSCLC. Patients with tumor MMP-9 expression had a
shorter DFS than those without tumor MMP-9 expression
(p = 0.01; Figure 2A). However, there was no significant
correlation between tumor MMP-9 expression and OS
(p = 0.109; Figure 3A).
Cox regression analysis was performed to evaluate
the correlation between tumor MMP-9 expression and
clinical outcomes. Tumor MMP-9 expression, age, LVI,
tumor histology, and tumor stage were tested as inde-
pendent possible prognostic variables. The resultsFigure 3 Kaplan-Meier survival curves of the relationship between tu
histology. (A) Overall tumor histology; (B) Squamous cell carcinoma; (C) Ademonstrated that tumor MMP-9 expression was not a
significant independent prognostic predictor for DFS
(p = 0.142), whereas LVI, stage, and tumor histology
were significant independent prognostic variables
(Table 2). Similarly, MMP-9 expression was not an in-
dependent predictor for OS (p = 0.807); LVI and tumor
stage were the only significant prognostic indicators for
OS (Table 3).
Analysis of DFS and OS by tumor histology
Clinicopathologic findings according to tumor histology
are shown in Table 4. In patients with squamous cell
carcinoma, tumor MMP-9 expression was not signifi-
cantly associated with DFS (p = 0.639: Figure 2B) or OS
(p = 0.510; Figure 3B). The results of the Cox regression
analysis showed that tumor MMP-9 expression was not
an independent prognostic indicator for DFS (Table 2)
or OS (Table 3).
However, among patients with adenocarcinoma, there
was a significant negative correlation between tumormor MMP-9 expression and overall survival according to tumor
denocarcinoma.
Table 2 Multivariate analysis of disease-free survival
Prognostic factor β P Relative
risk
95%
confidence
interval
Overall histology
Tumor MMP-9 expression 0.286 0.142 1.332 0.908–1.952
Lymphovascular invasion 0.586 0.028 1.797 1.065–3.032
Pathologic stage (I vs. II) 1.264 0.000 3.538 2.259–5.541
Pathologic stage (I vs. IIIA) 1.404 0.000 4.070 2.450–6.760
Tumor histology
(squamous cell carcinoma vs.
adeno)
0.685 0.002 1.985 1.299–3.033
Squamous cell carcinoma
Tumor MMP-9 expression −0.411 0.309 0.663 0.301–1.463
Adenocarcinoma
Tumor MMP-9 expression 0.580 0.035 1.787 1.041–3.067
MMP-9: matrix metalloproteinase-9; adeno: adenocarcinoma.
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and OS (p = 0.033; Figure 3C). Cox regression analysis
was used to define clinical markers with independent
predictive value with respect to DFS and OS. Tumor
MMP-9 positivity was an independent prognostic factor
for DFS (p = 0.035; Table 2); however, OS was not associ-
ated with MMP-9 expression (p = 0.259; Table 3).Discussion
MMPs are a group of zinc-dependent endopeptidases
that have been implicated in the degradation of extracel-
lular matrix. The role of MMPs in tumor growth, metas-
tasis, and angiogenesis has been widely investigated [18].
MMPs are divided into 4 subclasses according to their
substrate specificity: collagenases, gelatinases, stromelysins,
and elastases [19]. Among these, MMP-9 (gelatinase-B), a
crucial factor in angiogenesis, plays a critical role in the
progression of a variety of tumor types.Table 3 Multivariate analysis of overall survival
Prognostic factor β P Relative
risk
95%
confidence
interval
Overall histology
Tumor MMP-9 expression 0.043 0.807 1.044 0.741–1.469
Lymphovascular invasion 0.661 0.005 1.937 1.219–3.078
Pathologic stage (I vs. II) 0.904 0.000 2.469 1.686–3.616
Pathologic stage (I vs. IIIA) 1.123 0.000 3.073 1.938–4.875
Squamous cell carcinoma
Tumor MMP-9 expression −0.419 0.196 0.658 0.349–1.241
Adenocarcinoma
Tumor MMP-9 expression 0.295 0.259 1.343 0.805–2.242
MMP-9: matrix metalloproteinase-9.Expression levels of MMP-9 in serum and tissue are
significantly higher in patients with pancreatic ductal
adenocarcinoma than in those with pancreatitis [20],
and tumor MMP-9 expression is significantly elevated in
patients with breast cancer [21]. MMP-9 has been studied
as a prognostic factor for colorectal cancer in T3–T4
node-negative patients; enhanced tumor MMP-9 expres-
sion was found to be an independent marker of poor
prognosis [22]. However, in ovarian cancer, tumor
MMP-9 expression is associated with longer survival,
whereas stromal MMP-9 expression is associated with
shorter survival [23].
Many recent reports of tumor MMP-9 expression in
patients with operable NSCLC have suggested that
tumor MMP-9 expression is a predictor of poor progno-
sis [12,14,15]. However, the prognostic impact of IHC
detection of tumor MMP-9 expression in operable
NSCLC is controversial [16-19]. We therefore performed
this study to assess the prognostic impact of tumor
MMP-9 expression, as determined by IHC staining, in
patients with operable NSCLC.
There are certain limitations to studies of tumor
MMP-9 expression that may limit the interpretation of
the results. First, there were differences among previous
studies in the definition of tumor MMP-9 positivity and
the appropriate cut-off value. Most of these studies ap-
plied a scoring system that was based on the extent and
intensity of staining for tumor MMP-9 expression and
showed that overexpression of tumor MMP-9 was asso-
ciated with a poor prognosis [12,14,15]. Another study
used the median value of staining for tumor MMP-9 to
define tumor MMP-9 positivity [24]. However, there is
no common cut-off value for defining positive tumor
MMP-9 expression in NSCLC. In this study, an IHC
score was used to determine tumor expression levels of
MMP-9, and the median IHC score was used as the cut-
off value [25]. An IHC staining score of 10 (range, 0-
300) was used to divide patients into 2 groups, according
to the presence or absence of tumor MMP-9 expression.
In other words, an IHC score of less than 10 was defined
as an absence of tumor MMP-9 expression. The import-
ant point of our study was that tumor MMP-9 positivity
was not determined by a scoring system but by the pres-
ence or absence of tumor MMP-9 expression. Despite
efforts to standardize this process, a widely accepted
scoring system has not yet been established. Thus, our
dichotomous distinction for tumor MMP-9 expression
will reduce the impact of subjective judgment when de-
termining tumor MMP-9 positivity. In our study, 38.6%
of patients had tumor MMP-9 expression. However, if a
cut-off value of 20% was applied, tumor MMP-9 positivity
would be reduced to 27.3%. Our result of 38.6% seems
reasonable because it is consistent with the percentage of
patients showing tumor MMP-9 positivity in previous
Table 4 Patient characteristics by tumor histology
Tumor MMP-9
Squamous cell carcinoma Adenocarcinoma
No Expression Expression P No Expression Expression P
N (%) N (%) N (%) N (%)
Age 0.464 0.160
Below median 64 (49.2) 25 (55.6) 57 (55.3) 45 (45.5)
Above median 66 (50.8) 20 (44.4) 46 (44.7) 54 (54.5)
Sex 0.021 0.166
Male 121 (93.1) 36 (80.8) 41 (39.8) 49 (49.5)
Female 9 (6.9) 9 (20.2) 62 (60.2) 50 (50.5)
Stage 0.021 0.006
I 65 (50.0) 15 (33.4) 77 (74.7) 55 (55.6)
II 49 (37.7) 19 (42.2) 15 (14.6) 24 (24.2)
IIIA 16 (12.3) 11 (24.4) 11 (10.7) 20 (20.2)
T stage 0.042 0.019
T1 29 (22.3) 4 (8.9) 42 (40.8) 24 (24.2)
T2 75 (57.7) 29 (64.5) 55 (53.3) 67 (67.7)
T3 25 (19.2) 10 (22.2) 5 (4.9) 5 (5.1)
T4 1 (0.8) 2 (4.4) 1 (1.0) 3 (3.0)
N stage 0.183 0.008
N0 93 (71.6) 28 (62.2) 90 (87.4) 68 (68.7)
N1 31 (23.8) 13 (28.9) 3 (2.9) 14 (14.1)
N2 6 (4.6) 4 (8.9) 10 (9.7) 17 (17.2)
Lymphovascular invasion 0.832 0.740
No 111 (85.4) 39 (86.7) 94 (91.3) 89 (89.9)
Yes 19 (14.6) 6 (13.3) 9 (8.7) 10 (10.1)
Postoperative Treatment 0.299 0.001
Chemotherapy 41 (31.5) 18 (40.0) 24 (22.3) 42 (42.4)
Radiation 7 (5.4) 1 (2.2) 0 1 (1.0)
Combination 10 (7.7) 6 (13.3) 7 (6.8) 13 (13.1)
No treatment 72 (55.4) 20 (44.4) 72 (69.9) 43 (43.4)
MMP-9: matrix metalloproteinase-9; Combination: Chemotherapy + Radiation therapy.
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MMP-9 expression had more advanced stage (p = 0.001;
Table 1), therefore, they received more postoperative treat-
ment (p = 0.000; Table 1). However, there was no differ-
ence in adjuvant therapy for patients with stage II or IIIA
(72.4% vs. 71.4%; p = 0.879) and there was no statistical
difference in adjuvant therapy for histological type.
Second, it is important to interpret data according to
tumor histology. In previous studies, all types of tumor
histology were included in the analysis of tumor MMP-9
expression, and the value of the prognostic factors iden-
tified in these studies is controversial [16-19]. Some re-
ports have indicated that tumor MMP-9 expression is a
prognostic factor for adenocarcinoma of the lung
[11,24], and we analyzed that a higher proportion of theadenocarcinoma patients had positive tumor MMP-9 ex-
pression than squamous carcinoma in this study (28.0%
vs. 61.5%; p = 0.001). Thus, histological distinction (squa-
mous cell carcinoma vs. adenocarcinoma) seems to be
necessary in the analysis of tumor MMP-9 expression.
In the present study, the overall cohort included patients
with all histological types, including squamous cell car-
cinoma, adenocarcinoma, and large cell carcinoma.
When considering the total population, tumor MMP-9
expression was associated with an increased risk of re-
lapse (p = 0.01; Figure 2A) but was not predictive of OS
(p = 0.109; Figure 3A). Furthermore, when including all
tumor types, tumor MMP-9 expression was not an inde-
pendent prognostic factor for the additional outcomes
tested. After stratifying by tumor histology (squamous cell
Lee et al. Journal of Cardiothoracic Surgery  (2015) 10:44 Page 7 of 8carcinoma vs. adenocarcinoma), tumor MMP-9 expression
was associated with a poor prognosis for relapse (p =
0.003; Figure 2C) and OS (p = 0.033; Figure 3C) and was
an independent prognostic factor for relapse (p = 0.035;
Table 2) of adenocarcinoma of the lung. Moreover, previ-
ous studies included only limited analyses of tumor
MMP-9 expression in early-stage adenocarcinoma,
whereas this study evaluated stage I–IIIA operable adeno-
carcinoma of the lung [14,24].
Finally, it is difficult to analyze survival outcome ac-
cording to tumor MMP-9 expression. Survival outcomes
include both relapse and survival. MMP-9 is known to
be a key factor in the degradation of the extracellular
matrix and angiogenesis, processes related to tumor me-
tastasis. Therefore, it is reasonable to evaluate tumor
MMP-9 expression with respect to relapse, which in-
cludes both recurrence and metastasis, rather than with
respect to survival. Most previous studies have defined
the association of tumor MMP-9 expression in NSCLC
with a poor survival prognosis [12,14,15], and only a few
studies have shown the value of tumor MMP-9 expres-
sion for predicting relapse [18]. Our study demonstrated
that tumor MMP-9 expression was a significant and in-
dependent prognostic factor for the relapse of lung
adenocarcinoma.Conclusions
Tumor MMP-9 expression correlated with relapse in op-
erable NSCLC patients; however, we were not able to
demonstrate the clinical significance of tumor MMP-9
expression as a prognostic marker for relapse and sur-
vival. However, subgroup analyses of tumor histology
suggested that tumor MMP-9 expression was associated
with decreased DFS and OS in patients with adenocar-
cinoma but not in those with squamous cell carcinoma.
Moreover, in this study, Cox regression analysis revealed
that tumor MMP-9 expression was an independent poor
prognostic factor for the relapse of lung adenocarcin-
oma. Thus, more studies will be needed to confirm this,
and furthermore, IHC staining to distinguish tumor
MMP-9 expression may be useful to predict clinical out-
comes after surgical resection of lung adenocarcinoma.Consent
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